One consequence of systemic ARPI therapy could be reduced YAP/TEAD activation in tumor cells due to reduced ECM production by AR-positive stromal cells, thereby lowering the threshold for NEPC transition to occur. The gene discussed is YAP1; the disease is neoplasm.